Friday, October 30, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 28, 2026

Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow?

View original at nasdaq.com
Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow? Key Points The company had a fine second quarter, and investors will be hoping for a repeat…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Full-year 2026 comparable sales guidance raised to at least 5% growth (from more than 3% previously), and adjusted EPS guidance raised to $2.25-$2.45 (from $2.15-$2.40 previously)

    60% confidence

  • Analysts collectively expect Starbucks to post just over $9.1 billion in revenue and $0.65 per share in net income for fiscal Q3 2026 — nearly 4% below the prior-year revenue figure but a 30% improvement in EPS year over year

    60% confidence

  • Starbucks attributed its solid second-quarter performance to the Back to Starbucks initiative

    60% confidence

  • Starbucks is a mature business with a huge footprint that has little room to grow, and its stock is priced for hot growth with a forward P/E of almost 35 that profitability gains are unlikely to match; even a beat on Q3 earnings would not change this negative view

    60% confidence

Data points we hold from this source

Starbucks Corporation · forward pe35 ratio
Starbucks Corporation · stock price23 percent_ytd_change
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com
Is Starbucks's Stock a Buy Ahead of Its Q3 Earnings Report Tomorrow? — Source | Via News | Via News